Efecto de los antimaláricos sobre los diferentes dominios del índice de daño SLICC en pacientes de la cohorte GLADEL
Resumen
Objetivos: estimar el efecto de los antimaláricos (AM) sobre los diferentes dominios del índice de daño SLICC (SDI). Métodos: se estudiaron pacientes con diagnóstico clínico reciente (≤2 años) de lupus eritematoso sistémico (LES) de la cohorte GLADEL.Citas
I. Boumpas DT, Austin HA, 3rd, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Annals of internal medicine. 1995;122(12):940-50.
II. Boumpas DT, Fessler BJ, Austin HA, 3rd, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Annals of internal medicine. 1995;123(1):42-53.
III. BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheumatic diseases clinics of North America. 1995;21(1):81-98.
IV. Pons-Estel GJ, Alarcon GS, Gonzalez LA, Zhang J, Vila LM, Reveille JD, et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis care & research. 2010;62(3):393-400.
V. Pons-Estel GJ, Alarcon GS, McGwin G, Jr., Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis and rheumatism. 2009;61(6):830-9.
VI. Pons-Estel GJ, Gonzalez LA, Zhang J, Burgos PI, Reveille JD, Vila LM, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology. 2009;48(7):817-22.
VII. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Annals of the rheumatic diseases. 2007;66(9):1168-72.
VIII. Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. The Journal of rheumatology. 2013;40(6):831-41.
IX. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002;11(6):356-61.
X. Pons-Estel G WD, Ugarte-Gil M, et al 192 Protective effect of, erythematosus aotrodaisl, 10.1136/lupus-2017-000215.192 LSMd.
XI. Gonzalez LA, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS, et al. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus. 2009;18(9):822-30.
XII. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism. 1982;25(11):1271-7.
XIII. Pons-Estel GJ, Wojdyla D, McGwin G, Jr., Magder LS, Petri MA, Pons-Estel BA, et al. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus. 2014;23(1):3-9.
XIV. Gladman D, Urowitz M, Fortin P, Isenberg D, Goldsmith C, Gordon C, et al. Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. The Journal of rheumatology. 1996;23(11):1953-5.
XV. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis and rheumatism. 1997;40(5):809-13.
XVI. Dall’era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011;13(4):308-16.
XVII. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Annals of the rheumatic diseases. 2010;69(1):20-8.
XVIII. Pons-Estel GJ, Alarcon GS, Burgos PI, Hachuel L, Boggio G, Wojdyla D, et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus. 2013;22(9):899-907.
XIX. Pons-Estel GJ, Alarcon GS, Hachuel L, Boggio G, Wojdyla D, Pascual-Ramos V, et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology. 2012;51(7):1293-8.
XX. Shinjo SK, Bonfa E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis and rheumatism. 2010;62(3):855-62.
XXI. Fessler BJ, Alarcon GS, McGwin G, Jr., Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis and rheumatism. 2005;52(5):1473-80.
XXII. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70.
XXIII. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006;15(2):94-101.
XXIV. Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;17(4):281-8.
XXV. Garcia MA, Alarcon GS, Boggio G, Hachuel L, Marcos AI, Marcos JC, et al. Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort. Rheumatology. 2014;53(8):1431-8.
Derechos de autor 2018 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
